kurapwa hombe sero remapapu kurapwa

Kenza yekenza yemapapu yakakura (LCLC) iine hukasha subtype yeasiri diki cell kenza yemapapu (NSCLC). Nzira dzekurapa dzinowanzobatanidza musanganiswa wekuvhiya, chemotherapy, radiation therapy, yakanangwa kurapa, uye immunotherapy, yakarongedzwa nedanho remurwere, hutano hwese, uye chaiwo bundu maitiro. Kufambira mberi munguva pfupi yapfuura mukuongorora kwema molecular uye mushonga wemunhu uri kuvandudza zvinobuda kune avo vakaonekwa vaine LCLC.Kurapa kenza yemapapu hombe (LCLC) imhando yekenza yemapapu isiri diki. Inowana zita rayo kubva kumaseru makuru, asingatarisike anoonekwa pasi pemaikorosikopu. LCLC inokura nekupararira nekukurumidza, zvichiita kuti kuongororwa uye kurapwa kuve kwakakosha. Kunyange zvazvo isingawande kupfuura mamwe marudzi eNSCLC, kunzwisisa maitiro ayo kwakakosha pakutonga kunoshanda.Risk Factors and PreventionSezvakafanana nemamwe magomarara emapapu, kuputa ndiyo inotungamira njodzi yeLCLC. Zvimwe zvinokonzeresa njodzi zvinosanganisira kubatwa nehutsi hwefodya, radon, asbestos, uye zvimwe zvinhu zvemuindasitiri. Kurega kusvuta, kudzivisa kuratidzwa kune zvinozivikanwa zvinokonzera kenza, uye kuchengetedza mararamiro ane hutano ndiwo akanakisa ekudzivirira matanho. Kugara uchiongororwa uye kuongororwa kenza yemapapu kune vanhu vari panjodzi huru kunogonawo kubatsira mukuonekwa kwekutanga uye kunogona kuvandudza. hombe sero remapapu kurapwa Mishonga.Marapirwo eMarapi eSero Guru Regomarara Kuvhiyiwa kunowanzova nzira yekutanga yekurapa kweLCLC, apo bundu rinowanikwa munzvimbo uye risati rapararira kunzvimbo dziri kure. Kuvhiya kunogona kusanganisira kubvisa chikamu chemapapu (wedge resection kana segmentectomy), lobe rose (lobectomy), kana kunyange mapapu ose (pneumonectomy). Kusarudzwa kwekuvhiyiwa kunoenderana nehukuru uye nzvimbo yebundu, pamwe chete nemurwere wese wemapapu basa. Zvikwata zvekuvhiya zveShandong Baofa Cancer Research Institute zvine ruzivo rwakanyanya mumaitiro aya.ChemotherapyChemotherapy chirongwa chehurongwa chinoshandisa mishonga kuuraya maseru egomarara mumuviri wese. Inowanzo shandiswa musanganiswa nekuvhiyiwa kana neradiation therapy, kana sekutanga kurapwa kwepamberi-nhanho LCLC. Mishonga yakajairika yemakemotherapy yeLCLC inosanganisira mishonga yeplatinamu (senge cisplatin kana carboplatin) yakasanganiswa nemamwe chemotherapy agents. Migumisiro yekemotherapy inogona kusanganisira kusvotwa, kuneta, kurasikirwa nebvudzi, uye kuwedzera kwengozi yehutachiwana.Radiation TherapyRadiation therapy inoshandisa mwaranzi ine simba guru kunanga uye kuparadza masero ekenza. Inogona kushandiswa kurapa LCLC nenzira dzinoverengeka: sekutanga kurapwa kwevarwere vasiri kugadzirira kuvhiyiwa, seanorapa mushure mekuvhiyiwa kuuraya chero asara masero egomarara, kana kudzoreredza zviratidzo zvakadai sekurwadziwa kana kupfupika kwemweya muchirwere chepamusoro. Mhando dzekurapa nemwaranzi yemwaranzi inoshandiswa kuLCLC dzinosanganisira kunze kwebeam radiation therapy (EBRT) uye stereotactic body radiation therapy (SBRT).Targeted TherapyTargeted therapy mishonga inonangisa mamwe mamorekuru kana nzira dzine chekuita negomarara kukura uye kurarama. Mishonga iyi inonyanya kushanda kune varwere vane genetic mutations mumamota avo. Zvinangwa zvakajairika muLCLC zvinosanganisira EGFR, ALK, ROS1, uye BRAF. Vasati vatanga kurapwa kwakanangwa, varwere vanowanzo ongororwa mamorekuru kuti vaone kana mabundu avo aine chero yeaya ekuchinja anogona kuitika. Kana uchida rubatsiro, Baofa Cancer Research Institute inogona kukupa mabasa ekuongorora majini.ImmunotherapyImmunotherapy inoshandisa simba remasoja emuviri kurwisa gomarara. Immune checkpoint inhibitors, senge pembrolizumab, nivolumab, uye atezolizumab, imhando yeimmunotherapy inovhara mapuroteni anodzivirira immune system kurwisa cancer maseru. Immunotherapy yakaratidza mhedzisiro inovimbisa mukurapa LCLC, kunyanya muvarwere vane mamota anoratidza yakakwira PD-L1. Inogona kushandiswa senzira yekutanga kurapwa kweLCLC yepamusoro-soro kana mushure mokunge chemotherapy yakundikana.Kufambira mberi muSero Guru reMapapu Cancer TreatmentMolecular ProfilingMolecular profiling inosanganisira kuongorora bundu remurwere kuti rione kushanduka kwemajini chaiwo kana mamwe mamolecular alterations angave ari kutyaira kukura kwegomarara. Ruzivo urwu runogona kubatsira vanachiremba kusarudza iyo yakanyanya kunangwa kurapa kana immunotherapy kumurwere wega wega. Next-generation sequencing (NGS) inzira inowanzoshandiswa pakuongorora mamolecular, inobvumira kuonekwa panguva imwe chete yekuchinja kwemajini akawanda.Mushonga WemunhuMushonga wakasarudzika hombe sero remapapu kurapwa kumurwere wega wega zvichibva pane yavo bundu molecule chimiro, hutano hwese, uye zvavanoda. Iyi nzira ine chinangwa chekuwedzera kushanda kwekurapa uku uchideredza mhedzisiro. Mushonga wega wega uri kuramba uchikosha muhutungamiri hweLCLC, sezvo uchibvumira vanachiremba kuti vasarudze nzira yekurapa yakanyatsokodzera kumurwere wega wega.Clinical TrialsClinical miedzo itsvakurudzo zvidzidzo zvinoongorora marapirwo matsva kana kusanganiswa kwemishonga yeLCLC. Kutora chikamu mukuyedzwa kwekiriniki kunogona kupa varwere mukana wekucheka-kumucheto marapirwo ayo asati awanikwa zvakanyanya. Miedzo yemakiriniki chikamu chakakosha chekufambisira mberi kutarisirwa kwegomarara, uye varwere vanofanira kukurukura navanachiremba vavo kana kutora chikamu muchirongwa chekiriniki isarudzo yakanaka kwavari.Kufungidzira uye Kupona KwekuponaKurongeka kweLCLC kunosiyana zvichienderana nezvikonzero zvakawanda, kusanganisira danho rekenza pakuongororwa, hutano hwemurwere hwese, uye mhinduro yekurapwa. Early-stage LCLC iyo inorapwa nekuvhiyiwa ine fungidziro iri nani pane advanced-stage LCLC yakapararira kunzvimbo dziri kure. Kufambira mberi mukurapa, senge kwakanangwa kurapwa uye immunotherapy, kwakavandudza mararamiro evarwere vane LCLC mumakore achangopfuura. 5-Year Survival Rates yeNon-Small Cell Lung Cancer (NSCLC) by Stage1 Stage 5-Year Survival Rate Localized 63% Dunhu 36% Kure 8% All SEER Stage 26% *Cherechedza: Iyi mibairo yekupona inobva pane data kubva kuNational Cancer Institute's Surveillance, EpilRescutive Cell uye EpideLigure Programme (EpideLide Cell). Lung CancerKurarama neLCLC kunogona kuve kwakaoma, asi kune zviwanikwa zvekubatsira varwere nemhuri dzavo kurarama nemuviri uye manzwiro echirwere. Mapoka ekutsigira, kupa mazano, uye rubatsiro rwekunyaradza vanogona kupa rubatsiro rwakakosha. Kuchengeta mararamiro ane utano, kusanganisira kudya kwakadzikama uye kurovedza muviri nguva dzose, kunogonawo kuvandudza mararamiro ehupenyu. Kukurukura zvinokunetsa nemibvunzo nechikwata chezvehutano chako kwakakosha pakubata LCLC nemazvo.Kutsvaga Rutsigiro neZvishandisoMasangano akawanda anopa rutsigiro nezviwanikwa kune vanhu vakaonekwa vaine LCLC nemhuri dzavo. Zviwanikwa izvi zvinosanganisira zvekudzidzisa, mapoka ekutsigira, zvirongwa zvekubatsira mari, uye kuedza kwekukurudzira. Kubatana nezviwanikwa izvi kunogona kupa rubatsiro rwakakosha uye nhungamiro mukati merwendo rwegomarara.References: American Society of Clinical Oncology (ASCO): Kenza yeMapapu - Sero Risiri Diki: Nhamba.